These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 29429913)

  • 1. CAR T-cells for relapsed B-cell ALL in children and young adults.
    Stirrups R
    Lancet Oncol; 2018 Mar; 19(3):e144. PubMed ID: 29429913
    [No Abstract]   [Full Text] [Related]  

  • 2. CAR T-cells for relapsed B-cell ALL in adults.
    Gilbert JA
    Lancet Oncol; 2018 Mar; 19(3):e143. PubMed ID: 29429915
    [No Abstract]   [Full Text] [Related]  

  • 3. Trafficking of CAR T cells to sites of subclinical leukaemia cutis.
    O'Reilly M; Roddie C; Marzolini MAV; Rodriguez-Justo M; Pomplun S; Pule M; Peggs KS
    Lancet Oncol; 2020 Mar; 21(3):e179. PubMed ID: 32135121
    [No Abstract]   [Full Text] [Related]  

  • 4. Donor origin CAR19 T cell infusion for B-ALL relapsed after allogeneic hematopoietic stem cell transplantation.
    Yang X; Dai H; Kang L; Qu C; Li Z; Yin J; Qiu H; Fu C; Han Y; Jin Z; Ma X; Zhu X; Yu L; Wu D; Tang X
    Hematol Oncol; 2019 Dec; 37(5):655-658. PubMed ID: 31656047
    [No Abstract]   [Full Text] [Related]  

  • 5. How to Combine the Two Landmark Treatment Methods-Allogeneic Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Together to Cure High-Risk B Cell Acute Lymphoblastic Leukemia?
    Zhang M; Huang H
    Front Immunol; 2020; 11():611710. PubMed ID: 33384696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients.
    Pan J; Yang JF; Deng BP; Zhao XJ; Zhang X; Lin YH; Wu YN; Deng ZL; Zhang YL; Liu SH; Wu T; Lu PH; Lu DP; Chang AH; Tong CR
    Leukemia; 2017 Dec; 31(12):2587-2593. PubMed ID: 28490811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chimeric Antigen Receptor T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia.
    Tomuleasa C; Fuji S; Berce C; Onaciu A; Chira S; Petrushev B; Micu WT; Moisoiu V; Osan C; Constantinescu C; Pasca S; Jurj A; Pop L; Berindan-Neagoe I; Dima D; Kitano S
    Front Immunol; 2018; 9():239. PubMed ID: 29515572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Late Events After CD-19 CAR-T Treatment.
    Hossain NM; Nishimura MI
    Biol Blood Marrow Transplant; 2020 Jan; 26(1):e1-e2. PubMed ID: 31669398
    [No Abstract]   [Full Text] [Related]  

  • 9. CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease.
    Pehlivan KC; Duncan BB; Lee DW
    Curr Hematol Malig Rep; 2018 Oct; 13(5):396-406. PubMed ID: 30120708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful Treatment of TCF3-HLF-positive Childhood B-ALL with Chimeric Antigen Receptor T-Cell Therapy.
    Wang T; Wan X; Yang F; Shi W; Liu R; Ding L; Tang Y; Luo C; Yang X; Ma Y; Wang X; Liang H; Li B; Lu J; Chen J
    Clin Lymphoma Myeloma Leuk; 2021 Jun; 21(6):386-392. PubMed ID: 33640284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia.
    Pan J; Niu Q; Deng B; Liu S; Wu T; Gao Z; Liu Z; Zhang Y; Qu X; Zhang Y; Liu S; Ling Z; Lin Y; Zhao Y; Song Y; Tan X; Zhang Y; Li Z; Yin Z; Chen B; Yu X; Yan J; Zheng Q; Zhou X; Gao J; Chang AH; Feng X; Tong C
    Leukemia; 2019 Dec; 33(12):2854-2866. PubMed ID: 31110217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The differential effects of tumor burdens on predicting the net benefits of ssCART-19 cell treatment on r/r B-ALL patients.
    Li M; Xue SL; Tang X; Xu J; Chen S; Han Y; Qiu H; Miao M; Xu N; Tan J; Kang L; Yu Z; Lou X; Xu Y; Chen J; Yan Z; Feng W; Wu D; Yu L
    Sci Rep; 2022 Jan; 12(1):378. PubMed ID: 35013456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Efficacy of Chimeric Antigen Receptor T-Cell Therapy in Children With Central Nervous System Leukemia.
    Zhang L; Zuo Y; Lu A; Wu J; Jia Y; Wang Y; Zhang L
    Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e410-e414. PubMed ID: 33526401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An analytical biomarker for treatment of patients with recurrent B-ALL after remission induced by infusion of anti-CD19 chimeric antigen receptor T (CAR-T) cells.
    Zhang Y; Zhang W; Dai H; Wang Y; Shi F; Wang C; Guo Y; Liu Y; Chen M; Feng K; Zhang Y; Liu C; Yang Q; Li S; Han W
    Sci China Life Sci; 2016 Apr; 59(4):379-85. PubMed ID: 27009300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging role of immunotherapy in precursor B-cell acute lymphoblastic leukemia.
    Valecha GK; Ibrahim U; Ghanem S; Asti D; Atallah JP; Terjanian T
    Expert Rev Hematol; 2017 Sep; 10(9):783-799. PubMed ID: 28666090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of patient characteristics on chimeric antigen receptor T cell therapy in B-cell acute lymphoblastic leukemia.
    An F; Wang H; Liu Z; Wu F; Zhang J; Tao Q; Li Y; Shen Y; Ruan Y; Zhang Q; Pan Y; Zhu W; Qin H; Wang Y; Fu Y; Feng Z; Zhai Z
    Nat Commun; 2020 Nov; 11(1):5928. PubMed ID: 33230103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tisagenlecleucel (Kymriah) for ALL.
    Med Lett Drugs Ther; 2017 Oct; 59(1532):177-178. PubMed ID: 29039821
    [No Abstract]   [Full Text] [Related]  

  • 18. Chimeric Antigen Receptor T Cell Therapy During the COVID-19 Pandemic.
    Bachanova V; Bishop MR; Dahi P; Dholaria B; Grupp SA; Hayes-Lattin B; Janakiram M; Maziarz RT; McGuirk JP; Nastoupil LJ; Oluwole OO; Perales MA; Porter DL; Riedell PA;
    Biol Blood Marrow Transplant; 2020 Jul; 26(7):1239-1246. PubMed ID: 32298807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allogeneic chimeric antigen receptor T cells for children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
    Locatelli F; Del Bufalo F; Quintarelli C
    Haematologica; 2024 Jun; 109(6):1689-1699. PubMed ID: 38832424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chimeric Antigen Receptor (CAR) T-Cell Therapy.
    Pagel JM; West HJ
    JAMA Oncol; 2017 Nov; 3(11):1595. PubMed ID: 28880983
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.